CN1634292A - Traditional Chinese medicine for treating liver cancer and preparation process thereof - Google Patents
Traditional Chinese medicine for treating liver cancer and preparation process thereof Download PDFInfo
- Publication number
- CN1634292A CN1634292A CNA2004100507493A CN200410050749A CN1634292A CN 1634292 A CN1634292 A CN 1634292A CN A2004100507493 A CNA2004100507493 A CN A2004100507493A CN 200410050749 A CN200410050749 A CN 200410050749A CN 1634292 A CN1634292 A CN 1634292A
- Authority
- CN
- China
- Prior art keywords
- raw material
- medicinal raw
- peel
- chinese medicine
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 201000007270 liver cancer Diseases 0.000 title abstract description 35
- 208000014018 liver neoplasm Diseases 0.000 title abstract description 35
- 239000002994 raw material Substances 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000000706 filtrate Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 8
- 210000000582 semen Anatomy 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 13
- 238000005516 engineering process Methods 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- 201000011510 cancer Diseases 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 6
- 102000013529 alpha-Fetoproteins Human genes 0.000 abstract description 5
- 108010026331 alpha-Fetoproteins Proteins 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 239000000047 product Substances 0.000 abstract description 4
- 241000746716 Typhonium Species 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 241000758789 Juglans Species 0.000 abstract description 2
- 244000264601 Juglans mandschurica Species 0.000 abstract description 2
- 235000009496 Juglans regia Nutrition 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 235000020234 walnut Nutrition 0.000 abstract description 2
- 206010004542 Bezoar Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 240000000774 Cunila origanoides Species 0.000 abstract 1
- 235000018274 Cunila origanoides Nutrition 0.000 abstract 1
- 235000014866 Dictamnus albus Nutrition 0.000 abstract 1
- 235000014075 Juglans mandschurica Nutrition 0.000 abstract 1
- 241001092391 Sorbus Species 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 239000007888 film coating Substances 0.000 abstract 1
- 238000009501 film coating Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 235000008345 mountainash Nutrition 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229930192392 Mitomycin Natural products 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- JWJLXIJFFIWQPE-UHFFFAOYSA-N acetic acid;ethyl acetate;hexane;methanol Chemical compound OC.CC(O)=O.CCCCCC.CCOC(C)=O JWJLXIJFFIWQPE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Chinese medicament for treating liver cancer and process for preparation, wherein the product is named as sanjie tablet. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: giant typhonium rhizome, dittany bark, walnut mountain ash green peel, artificial bezoar 1950-300-1400-600-160-120-6-3. The preparation process comprises the following steps: decocting rhizoma typhonii, cortex dictamni and Chinese walnut green fruit peel in water twice according to the weight ratio of the medicinal materials, wherein the water adding amount for the first time is 12 times of the total weight of the medicinal materials, the decocting time is 2 hours, the water adding amount for the second time is 8 times of the total weight of the medicinal materials, the decocting time is 1 hour, the filtering is carried out, the filtrates are combined and concentrated to form clear paste with the relative density of 1.35-1.38 and the temperature of 70 ℃, the clear paste is dried under reduced pressure, crushed, artificial bezoar fine powder and auxiliary materials are added, the mixture is uniformly mixed, granulated by 75% ethanol, dried, pressed into tablets and coated with film coatings, thus obtaining the Chinese medicinal. The advantages are that: clearing away heat and toxic material, softening and resolving hard mass, promoting blood circulation and removing blood stasis. Has the functions of improving the immunity of the organism, inhibiting the alpha-fetoprotein and resisting cancer obviously.
Description
Technical field
The present invention relates to a kind of Chinese medicine and preparation technology thereof who treats hepatocarcinoma, its name of product is---liver cancer tablet.
Background technology
In recent years, primary hepatocarcinoma is one of disease of serious harm people life and health, because this disease is asymptomatic in early days, seldom can in time be found except that generaI investigation; And the mid and late liver cancer PD is fast, and most patients have lost the chance of operation because of the later of discovery.In treatment, how insensitive primary hepatocarcinoma is to chemotherapy, radiotherapy, and chemotherapy and radiation can produce intensive side effect to human body, and weak curative effect, patient death rate height.Therefore, developing a kind of medicine that can treat hepatocarcinoma effectively is one of important topic in the current oncotherapy.
The applicant applied for patent of invention to State Patent Office on 16th in December in 1993; its application number is " 93115971.7 "; this patent documentation discloses a kind of liver cancer tablet and preparation method thereof; this Chinese medicine liver cancer tablet is made up of Rhizoma Typhonium Gigantei (Rhizoma Typhonii), Cortex Dictamni, Fructus Juglandis mandshuricae and Calculus Bovis, and its weight ratio is 300: 267: 45: 1.Prove by clinical trial,, cause the effect of its treatment hepatocarcinoma relatively poor because of its prescription and proportioning are perfect inadequately.Therefore, need courageously improve and innovate, prescription and proportioning are tending towards rationally, each component synergism just can make it to hepatocarcinoma raising evident in efficacy.
Summary of the invention
The present invention is directed to the technical problem of above-mentioned existence and a kind of Chinese medicine and preparation technology thereof who treats hepatocarcinoma is provided, it has broken through the forbidden zone of present Chinese medicine dosage, and with Semen Juglandis peel replacement Fructus Juglandis mandshuricae the effect of treatment hepatocarcinoma is significantly increased.
The present invention treats the Chinese medicine of hepatocarcinoma and is made up of by weight following medicinal raw material:
Rhizoma Typhonii: Cortex Dictamni: Semen Juglandis peel: artificial Calculus Bovis=1950-300: 1400-600: 160-120: 6-3.
The present invention treats the Chinese medicine of hepatocarcinoma and is made up of by optimum weight ratio following medicinal raw material:
Rhizoma Typhonii: Cortex Dictamni: Semen Juglandis peel: artificial Calculus Bovis=1900: 900: 135: 3.
The Chinese medicine preparation technology that the present invention treats hepatocarcinoma is: the weight ratio by above-mentioned medicinal raw material is got Rhizoma Typhonii; Cortex Dictamni; Semen Juglandis peel decocts with water secondary; amount of water is 12 times that above-mentioned medicinal raw material weight adds up to for the first time; decocted 2 hours; amount of water is 8 times that above-mentioned medicinal raw material weight adds up to for the second time; decocted 1 hour, and filtered, it is 1.35～1.38 that merging filtrate is concentrated into relative density; temperature is 70 ℃ a clear paste; drying under reduced pressure is pulverized, and adds artificial Calculus Bovis's fine powder and adjuvant; mixing; use 75% alcohol granulation, drying, compacting is in flakes; the bag film-coat, promptly.
Advantageous effect of the present invention:
1, the present invention courageously improves and innovates, broken through the forbidden zone of present Chinese medicine dosage, as the dosage of Rhizoma Typhonii more than 20 times of Chinese medicine dosage, and replace Fructus Juglandis mandshuricae with Semen Juglandis peel, prescription of the present invention and proportioning are more reasonable, each component synergism is significantly increased the effect of treatment hepatocarcinoma.
2, the present invention has the heat of dispelling dispel temperature, detoxifcation pain relieving, blood stasis-eliminating and stagnation-dissipating function, the rich primary hepatocarcinoma of becoming main symptom of the wet stasis of blood there is certain cancer remission rate, disease to the rich knot card of the wet stasis of blood has some improvement simultaneously, improves patient's life quality, prolongs life cycle.
3, the present invention and intervention filling chemotherapy is share, and can improve the effective percentage of getting involved chemotherapy, and can play Attenuation.Can be used for hepatocarcinoma and digestive tract tumor, also can be used as the adjuvant therapy medicaments of cancer.But human body immunity improving function, inhibition alpha-fetoprotein have significant antitumaous effect.
The present invention treats the clinical experiment report of the Chinese medicine of hepatocarcinoma
Clinical experiment method of the present invention is as follows:
Treatment group now and matched group, existing liver cancer tablet group and former liver cancer tablet group compare, treatment group now is to be combined with the intervention chemotherapeutic by liver cancer tablet of the present invention case is treated, matched group is with getting involved chemotherapeutic case to be treated, existing liver cancer tablet group is with liver cancer tablet of the present invention case to be treated, and former liver cancer tablet is case to be treated for the former liver cancer tablet of " 93115971.7 " with application number.
Clinical trial drug usage of the present invention is as follows:
(1) liver cancer tablet usage:
1, medicine: liver cancer tablet of the present invention and former liver cancer tablet;
2, usage: every day three times, each six, oral.
(2) chemotherapeutic operational version:
1, chemotherapeutics: be homemade ministry standard.
Mitomycin 2mg/ bottle; Cisplatin 20mg/ bottle
2, chemotherapy regimen
Mitomycin 10mg tremulous pulse injects, and cisplatin 80mg tremulous pulse injects
One, total effects
The present invention's treatment group now total effective rate 61%, matched group total effective rate are 43%, two group relatively significant difference; Existing liver cancer tablet group total effective rate 32%, former liver cancer tablet group total effective rate 26.7%, existing liver cancer tablet group and former liver cancer tablet group relatively have significant difference; As shown in table 1, each phase efficacy analysis is as shown in table 2:
Table 1 total effects
| Example | Produce effects | Effectively | Invalid | Effective percentage % | |
| Treatment group now | ??100 | ??20 | ??41 | ??39 | ????61.0 |
| Matched group | ??100 | ??11 | ??32 | ??57 | ????43.0 |
| Existing liver cancer tablet group | ??100 | ??3 | ??29 | ??68 | ????32.0 |
| Former liver cancer tablet group | ??30 | ??1 | ??7 | ??22 | ????26.7 |
Treatment group now and matched group compare: u=2.43, P＜0.05
Table 2 is respectively organized each phase efficacy analysis
| Phase | The example number | Produce effects | Effectively | Invalid | |
| Treatment group now | ????I?II | ????100 | ????20 | ????41 | ????39 |
| Matched group | ????I?II | ????100 | ????11 | ????32 | ????57 |
| Existing liver cancer tablet group | ????II | ????47 | ????3 | ????12 | ????32 |
| Existing liver cancer tablet group | ????III | ????53 | ????0 | ????17 | ????36 |
| Former liver cancer tablet group | ????I?II?III | ????30 | ????1 | ????7 | ????26.7 |
I II phase treatment group now and matched group compare: u=2.43, P＜0.05
Two, cancer curative effect
According to WHO cancer evaluation criteria, the cancer remission rate of the present invention's treatment group now was 52% (I II phase), and matched group cancer remission rate was 35% (I II phase), and two groups relatively have the difference (P＜0.05) of highly significant as shown in table 3:
Table 3 cancer curative effect
| Example | Alleviate fully | Part is alleviated | Stable | Worsen | Total remission rate (%) | |
| Treatment group now | ??100 | ????0 | ????20 | ????41 | ????39 | ??52.0 |
| Matched group | ??100 | ????0 | ????11 | ????32 | ????57 | ??35.0 |
| Existing liver cancer tablet group | ??100 | ????0 | ????4 | ????70 | ????26 | ??4.0 |
| Former liver cancer tablet group | ??30 | ????0 | ????1 | ????18 | ????11 | ??3.3 |
Treatment group now and matched group compare: x
2=5.88, P＜0.05 (alleviating and not alleviating comparison)
Three, alpha-fetoprotein determination
Feminine gender totally 330 examples after measured, the alph-fetoprotein positive person is 284 examples, accounts for 86%, alpha-fetoprotein determination value distribution situation is not all having significant difference between existing treatment group and matched group, see table 4 for details:
Table 4 alpha-fetoprotein (ng/ml) distribution situation
| The example number | ??＜25 | ??25～ | ??200～ | ???400～ | |
| Treatment group now | ????100 | ????9 | ????13 | ????9 | ????69 |
| Matched group | ????100 | ????15 | ????6 | ????7 | ????72 |
| Existing liver cancer tablet group | ????100 | ????18 | ????7 | ????12 | ????63 |
| Former liver cancer tablet group | ????30 | ????3 | ????2 | ????3 | ????22 |
Treatment group now and matched group compare: u=0.15, P＞0.05
Four, life quality efficacy analysis
Life quality efficacy analysis of the present invention is totally 300 examples, and the life quality distribution situation of existing treatment group and matched group is shown in table 5,6:
Table 5 life quality efficacy analysis
| The example number | Produce effects | Effectively | Invalid | Effective percentage % | |
| Treatment group now | ????100 | ????9 | ????46 | ????45 | ????55.0 |
| Matched group | ????100 | ????4 | ????36 | ????60 | ????41.0 |
| Existing liver cancer tablet group | ????100 | ????0 | ????44 | ????56 | ????44.0 |
Treatment group now and matched group be (Ridit): u=1.95 relatively, P＞0.05
Table 6 is respectively organized each phase life quality efficacy analysis
| Example | Phase | Invalid | Effectively | Produce effects | Effective percentage % | |
| Treatment group now | 100 | ????I?II | ????39 | ????50 | ????11 | ????61.0 |
| Matched group | 100 | ????I?II | ????53 | ????40 | ????7 | ????47.0 |
| Existing liver cancer tablet group | 47 | ????II | ????31 | ????13 | ????3 | ????34 |
| Existing liver cancer tablet group | 53 | ????III | ????30 | ????20 | ????3 | ????43 |
Treatment group now and matched group compare: u=1.95, P＞0.05
Untoward reaction:
(1) taking medicine afterwards, the cardiopalmus symptom can appear in small number of patients.
(2) there is small number of patients hematochrome, platelet, liver function, change in renal function to occur in the clinical trial of the present invention, but fails to judge relevant with use the present invention.
Curative effect of the present invention is summed up:
According to the clinical experiment data of several indexs, now the curative effect total effective rate of treatment group is 61% as can be known, and the curative effect total effective rate of matched group is 43%, existing treatment group and matched group comparison both there were significant differences, mainly reflect following several aspect:
1, liver cancer tablet of the present invention has certain tumor-inhibiting action, and its cancer remission rate is very obvious, share potentiation with chemotherapy and is significantly improved with the matched group ratio.
2, liver cancer tablet of the present invention and chemotherapy are share life quality and matched group than also improving.
Differentiate and detection
1, the character of liver cancer tablet of the present invention: be the blue membrane garment piece, remove and show sepia, gas burnt odor, mildly bitter flavor suffering behind the film-coat.
2, differentiate:
(1) get 10 of the present invention, remove film-coat, porphyrize adds chloroform 50ml, and supersound process 30 minutes filters, and flings to chloroform, and residue adds methanol 2ml makes dissolving, as need testing solution.Other gets Cortex Dictamni control medicinal material 2g, shines medical material solution in pairs with legal system.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw need testing solution 10-15 μ l, control medicinal material solution 1-3 μ l, put respectively in same and contain on the silica gel g thin-layer plate that Sodium Tvlose is an adhesive, with normal hexane-ethyl acetate (3: 2) is developing solvent, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to be heated to the speckle colour developing in 105 ℃.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color.
(2) get 4 of the present invention, remove film-coat, porphyrize adds dehydrated alcohol 10ml, grind dissolving, filter, filtrate is concentrated into about 1ml, as need testing solution, other gets cholic acid, Hyodeoxycholic Acid reference substance, adds dehydrated alcohol and makes the mixed solution that every 1ml contains 1ml, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw need testing solution 10-15 μ l, reference substance solution 2 μ l, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with chloroform-ether-glacial acetic acid (5: 5: 2) is developing solvent, launch, take out, dry, spray is with 10% phosphomolybdic acid ethanol solution, and it is clear to be heated to the speckle colour developing in 105 ℃.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
3, check: should meet every regulation relevant under the tablet item (appendix ID of Chinese Pharmacopoeia version in 2000).
4, assay: get 20 of the present invention, remove film-coat, the accurate title, decide, porphyrize, precision take by weighing the about 1.5g of fine powder, put in the tool plug conical flask, the accurate methanol 50ml that adds, close plug claims to decide weight, supersound process 30 minutes is put coldly, claims to decide weight, supply the weight that subtracts mistake with methanol, shake up, filter, precision is measured subsequent filtrate 25ml, and evaporate to dryness, residue add 20% sodium hydroxide solution 10ml, reflux 2 hours, cooling adds dilute hydrochloric acid and transfers pH to acid, with 4 (25ml of ethyl acetate extraction, 25ml, 20ml, 20ml), ethyl acetate liquid all filters by the same absorbent cotton that is covered with a small amount of anhydrous sodium sulfate, merge extractive liquid,, evaporate to dryness in the water-bath, residue add dissolve with methanol and are transferred in the 10ml measuring bottle, add methanol to scale, shake up, as need testing solution.Precision takes by weighing the cholic acid reference substance that is dried to constant weight through 105 ℃ in addition, adds methanol and makes the solution that every 1ml contains 0.45mg, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), the accurate need testing solution 10 μ l that draw, reference substance solution 1 μ l and 3 μ l, respectively the cross point in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, (20: 25: 2: upper solution 3) was developing solvent with hexane-ethyl acetate-acetic acid-methanol, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to be heated to the speckle colour developing in 105 ℃, takes out, on lamellae, cover onesize glass plate, use immobilization with adhesive tape on every side.Scan wavelength according to thin layer chromatography (an appendix VIB of Chinese Pharmacopoeia version in 2000 thin layer chromatography scanning): λ
s=380mm, λ
R=650mm measures test sample trap integrated value and reference substance trap integrated value, calculates, promptly.
Every of the present invention contains the artificial Calculus Bovis with cholic acid (C
24H
40O
5) meter, must not be less than 0.15mg,
Item such as function and consumption
1, function cures mainly: have the heat of dispelling dispel temperature, detoxifcation pain relieving, blood stasis-eliminating and stagnation-dissipating function, the rich primary hepatocarcinoma of becoming main symptom of the wet stasis of blood there is certain cancer remission rate, disease to the rich knot card of the wet stasis of blood has some improvement simultaneously, improves patient's life quality, prolongs life cycle.Share with getting involved the filling chemotherapy, can improve the effective percentage of getting involved chemotherapy, and can play Attenuation.Can be used for hepatocarcinoma and digestive tract tumor, also can be used as the adjuvant therapy medicaments of cancer.
2, usage and dosage: use simultaneously with getting involved chemotherapy, oral, one time 6,3 times on the one, one after each meal.I, II phase patient 2 months were 1 course of treatment, and III phase patient 1 month was 1 course of treatment.
3, points for attention:
(1) the present invention should use under physician guidance.
(2) Rhizoma Typhonii large usage quantity in the present invention's prescription please notes control dosage, the course of treatment.
(3) in the use of the present invention, as tongue lip numbness appears, symptoms such as throat is scorching hot, tongue body is stiff, slurred speech, need vigilant Rhizoma Typhonii to poison drug withdrawal in time, processing.
4, taboo: period in a medicine is given up alcohol.
5, specification: every heavy 0.3g needs the sealing storage; Effect duration of the present invention is tentative to be 2 years.
6, packing: (1) plastic bottle, 72 slices/bottle; (2) aluminium foil, 12 * 3 plates/box.
The present invention is described in further detail below in conjunction with embodiment.
The specific embodiment
Embodiment 1:
The present invention treats the Chinese medicine of hepatocarcinoma and is made up of by weight following medicinal raw material:
Rhizoma Typhonii: Cortex Dictamni: Semen Juglandis peel: artificial Calculus Bovis=1950: 1400: 160: 6.
Semen Juglandis peel is the immature peel of walnut Juglans mandshurica Juglans Mandshurica Maxim.Pluck fruit and get peel the first tenday period of a month August in autumn, dries or cold drying.
The Chinese medicine preparation technology that the present invention treats hepatocarcinoma is:
By the weight ratio of above-mentioned medicinal raw material get Rhizoma Typhonii (Rhizoma Typhonium Gigantei (Rhizoma Typhonii)) 1950g, Cortex Dictamni 1400g, Semen Juglandis peel 160g decoct with water secondary; amount of water is 12 times that above-mentioned medicinal raw material weight adds up to for the first time; decocted 2 hours; amount of water is 8 times that above-mentioned medicinal raw material weight adds up to for the second time; decocted 1 hour, and filtered, it is 1.35～1.38 that merging filtrate is concentrated into relative density; temperature is 70 ℃ a clear paste; drying under reduced pressure is pulverized, and adds artificial Calculus Bovis fine powder 6g and adjuvant; mixing; use 75% alcohol granulation, drying is pressed into 1000; the bag film-coat, promptly.
Embodiment 2:
The present invention treats the Chinese medicine of hepatocarcinoma and is made up of by optimum weight ratio following medicinal raw material:
Rhizoma Typhonii: Cortex Dictamni: Semen Juglandis peel: artificial Calculus Bovis=1900: 900: 135: 3.
The Chinese medicine preparation technology that the present invention treats hepatocarcinoma is:
By the weight ratio of above-mentioned medicinal raw material get Rhizoma Typhonii 1900g, Cortex Dictamni 900g, Semen Juglandis peel 135g decocts with water secondary; amount of water is 12 times that above-mentioned medicinal raw material weight adds up to for the first time; decocted 2 hours; amount of water is 8 times that above-mentioned medicinal raw material weight adds up to for the second time; decocted 1 hour, and filtered, it is 1.35～1.38 that merging filtrate is concentrated into relative density; temperature is 70 ℃ a clear paste; drying under reduced pressure is pulverized, and adds artificial Calculus Bovis fine powder 3g and adjuvant; mixing; use 75% alcohol granulation, drying is pressed into 1000; the bag film-coat, promptly.
Embodiment 3:
The present invention treats the Chinese medicine of hepatocarcinoma and is made up of by weight following medicinal raw material:
Rhizoma Typhonii: Cortex Dictamni: Semen Juglandis peel: artificial Calculus Bovis=300: 600: 120: 5.
The Chinese medicine preparation technology that the present invention treats hepatocarcinoma is:
By the weight ratio of above-mentioned medicinal raw material get Rhizoma Typhonii 300g, Cortex Dictamni 600g, Semen Juglandis peel 120g decocts with water secondary; amount of water is 12 times that above-mentioned medicinal raw material weight adds up to for the first time; decocted 2 hours; amount of water is 8 times that above-mentioned medicinal raw material weight adds up to for the second time; decocted 1 hour, and filtered, it is 1.35～1.38 that merging filtrate is concentrated into relative density; temperature is 70 ℃ a clear paste; drying under reduced pressure is pulverized, and adds artificial Calculus Bovis fine powder 5g and adjuvant; mixing; use 75% alcohol granulation, drying, compacting is in flakes; the bag film-coat, promptly.
Claims (4)
1, a kind of Chinese medicine for the treatment of hepatocarcinoma, it is characterized in that it by following medicinal raw material by weight forming:
Rhizoma Typhonii: Cortex Dictamni: Semen Juglandis peel: artificial Calculus Bovis=1950-300: 1400-600: 160-120: 6-3.
2, the Chinese medicine of treatment hepatocarcinoma according to claim 1, it is characterized in that it by following medicinal raw material by weight forming:
Rhizoma Typhonii: Cortex Dictamni: Semen Juglandis peel: artificial Calculus Bovis :=1900: 900: 135: 3.
3, a kind of preparation technology who treats the Chinese medicine of hepatocarcinoma, it is characterized in that it by following medicinal raw material by weight forming:
Rhizoma Typhonii: Cortex Dictamni: Semen Juglandis peel: artificial Calculus Bovis=1950-300: 1400-600: 160-120: 6-3;
Its preparation technology is:
Get Rhizoma Typhonii, Cortex Dictamni, Semen Juglandis peel by the weight ratio of above-mentioned medicinal raw material and decoct with water secondary; amount of water is 12 times that above-mentioned medicinal raw material weight adds up to for the first time; decocted 2 hours; amount of water is 8 times that above-mentioned medicinal raw material weight adds up to for the second time; decocted 1 hour, and filtered, it is 1.35～1.38 that merging filtrate is concentrated into relative density; temperature is 70 ℃ a clear paste; drying under reduced pressure is pulverized, and adds artificial Calculus Bovis's fine powder and adjuvant; mixing; use 75% alcohol granulation, drying, compacting is in flakes; the bag film-coat, promptly.
4, the Chinese medicine of treatment hepatocarcinoma according to claim 3, it is characterized in that it by following medicinal raw material by weight forming:
Rhizoma Typhonii: Cortex Dictamni: Semen Juglandis peel: artificial Calculus Bovis=1900: 900: 135: 3;
Its preparation technology is: get Rhizoma Typhonii, Cortex Dictamni, Semen Juglandis peel by the weight ratio of above-mentioned medicinal raw material and decoct with water secondary; amount of water is 12 times that above-mentioned medicinal raw material weight adds up to for the first time; decocted 2 hours; amount of water is 8 times that above-mentioned medicinal raw material weight adds up to for the second time; decocted 1 hour, and filtered, it is 1.35～1.38 that merging filtrate is concentrated into relative density; temperature is 70 ℃ a clear paste; drying under reduced pressure is pulverized, and adds artificial Calculus Bovis's fine powder and adjuvant; mixing; use 75% alcohol granulation, drying, compacting is in flakes; the bag film-coat, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100507493A CN1314424C (en) | 2004-10-29 | 2004-10-29 | Traditional Chinese medicine for treating liver cancer and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100507493A CN1314424C (en) | 2004-10-29 | 2004-10-29 | Traditional Chinese medicine for treating liver cancer and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634292A true CN1634292A (en) | 2005-07-06 |
| CN1314424C CN1314424C (en) | 2007-05-09 |
Family
ID=34846062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100507493A Expired - Lifetime CN1314424C (en) | 2004-10-29 | 2004-10-29 | Traditional Chinese medicine for treating liver cancer and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1314424C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100427099C (en) * | 2006-03-02 | 2008-10-22 | 上海交通大学 | Juglans mandshurica maxim pdysaccharide preparation capable of effectively treating brain cancer and its preapring method |
| CN106383195A (en) * | 2016-08-29 | 2017-02-08 | 贵州信邦制药股份有限公司 | Identification method of cortex dictamni in anti-rheumatism medicinal liquor |
| CN113368179A (en) * | 2021-05-15 | 2021-09-10 | 珠海米迪泰克生物制药有限公司 | Preparation method of anti-liver cancer medicine tablet |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095949A (en) * | 1993-12-16 | 1994-12-07 | 刘今方 | A kind of liver cancer tablet and preparation method thereof |
| CN1058179C (en) * | 1997-07-29 | 2000-11-08 | 刘今方 | Xiaojieling and preparation process thereof |
-
2004
- 2004-10-29 CN CNB2004100507493A patent/CN1314424C/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100427099C (en) * | 2006-03-02 | 2008-10-22 | 上海交通大学 | Juglans mandshurica maxim pdysaccharide preparation capable of effectively treating brain cancer and its preapring method |
| CN106383195A (en) * | 2016-08-29 | 2017-02-08 | 贵州信邦制药股份有限公司 | Identification method of cortex dictamni in anti-rheumatism medicinal liquor |
| CN106383195B (en) * | 2016-08-29 | 2018-08-21 | 贵州信邦制药股份有限公司 | The discrimination method of the root bark of shaggy-fruited dittany in anti-rheumatism medicinal liquor |
| CN113368179A (en) * | 2021-05-15 | 2021-09-10 | 珠海米迪泰克生物制药有限公司 | Preparation method of anti-liver cancer medicine tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1314424C (en) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1768854A (en) | Chinese medicinal capsule with spleen-supplementing, intestine-benefiting function | |
| CN101057925B (en) | Preparation technology for 'jieguqili' capsule | |
| CN1316990C (en) | Chinese medicinal composition, preparation method and quality control method thereof | |
| CN1850161A (en) | Medicine composition for treating pain and preparing method therefor | |
| CN1836706A (en) | Chinese traditional medicine composition for treating leucopenia and preparation and quality controlling method thereof | |
| CN1314424C (en) | Traditional Chinese medicine for treating liver cancer and preparation process thereof | |
| CN112755160A (en) | Traditional Chinese medicine composition for improving postoperative prognosis of breast cancer and application thereof | |
| CN1709341A (en) | Medicinal composition for nourishing qi to invigorate spleen, and its preparing method and use | |
| CN1292778C (en) | Chinese medicine composition for stopping itching and its preparing method | |
| CN101028348A (en) | Chinese medicinal capsule, its production and quality controlling method | |
| CN101129974A (en) | Traditional Chinese medicine composition for treating hepatopathy and method of preparing the same | |
| CN1887324A (en) | Chinese composition and its prepn process and quality control method | |
| CN1891285A (en) | Chinese medicine composition, and its preparing method and quality control method | |
| CN1689626A (en) | Traditional Chinese medicine compound recipe for treating hyperplasia of mammary glands and preparation method thereof | |
| CN100336544C (en) | Chinese medicinal composition with beautifying function and method for preparing the same | |
| CN1657093A (en) | Preparation method of granular agent for raising leucocyte and its quality control method | |
| CN1709288A (en) | Medicinal composition, and its preparing method and use | |
| CN1961898A (en) | An antitumor compound pharmaceutical composition with barbed stullcap and preparation process thereof | |
| CN1083721C (en) | Compound Chinese herb medicine for curing fibrosis of liver and hepatocirrhosis and its preparation method | |
| CN1785212A (en) | Novel cinobufogenin freeze-drying powder injection, its prepn. method and quality control method | |
| CN1299757C (en) | Chinese medicinal composition for treating scapulohumeral periarthritis and preparing method thereof | |
| CN1220510C (en) | Chinese patent medicine with the functions of replenishing qi and blood and nourishing the heart to calm the mind, its preparation method and quality control method | |
| CN1480173A (en) | Chinese herbal medicine for treating gynecology disease and its preparing method | |
| CN1241586C (en) | Chinese medicine composition and preparing method thereof | |
| CN1220513C (en) | Proprietury Chinese medicine for stopping blood, analgesia, removing blood stasis and engender new and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENYANG JINFANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIU JINFANG Effective date: 20110120 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110161 NO.21-4, XINLIBAO STREET, DONGLING DISTRICT, SHENYANG CITY, LIAONING PROVINCE SHENYANG JINFANG PHARMACEUTICAL CO., LTD. TO: 110161 NO.21-4, XINLIBAO STREET, DONGLING DISTRICT, SHENYANG CITY, LIAONING PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110120 Address after: 110161, 21-4 Fort Street, Dongling District, Liaoning, Shenyang Patentee after: Shenyang today pharmaceutical LLC Address before: 110161 Shenyang Shenyang Pharmaceutical Co., Ltd., 21-4 Lixin street, Dongling District, Liaoning, China Patentee before: Liu Jinfang |
|
| ASS | Succession or assignment of patent right |
Owner name: WU XIUKUN Free format text: FORMER OWNER: SHENYANG JINFANG PHARMACEUTICAL CO., LTD. Effective date: 20121115 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CI01 | Publication of corrected invention patent application |
Correction item: Patentee Correct: Shenyang today Pharmaceutical Co.,Ltd.|110161, 21-4 Fort Street, Dongling District, Liaoning, Shenyang False: Shenyang today pharmaceutical LLC|110161, 21-4 Fort Street, Dongling District, Liaoning, Shenyang Number: 10 Volume: 27 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110161 SHENYANG, LIAONING PROVINCE TO: 518000 SHENZHEN, GUANGDONG PROVINCE |
|
| ERR | Gazette correction | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20121115 Address after: 518000, Guangdong, Shenzhen province Luohu District cloth Road No. 1023 East music garden Le Kang building 21E Patentee after: Wu Xiukun Address before: 110161, 21-4 Fort Street, Dongling District, Liaoning, Shenyang Patentee before: Shenyang today Pharmaceutical Co.,Ltd. |
|
| CB03 | Change of inventor or designer information |
Inventor after: Wu Xiukun Inventor before: Liu Jinfang |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180515 Address after: 519090 first floor, office building, 150 Gate Road, San Zao Town, Jin Wan District, Zhuhai, Guangdong. Patentee after: ZHUHAI MIDI TAIKE BIO-PHARMACEUTICAL CO.,LTD. Address before: 518000 Le Kang building, 1023 Dongxin Road, Luohu District, Shenzhen, Guangdong, 21E Patentee before: Wu Xiukun |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181010 Address after: 519090 first floor, office building, 150 Gate Road, San Zao Town, Jin Wan District, Zhuhai, Guangdong. Co-patentee after: Wu Xiukun Patentee after: ZHUHAI MIDI TAIKE BIO-PHARMACEUTICAL CO.,LTD. Address before: 519090 first floor, office building, 150 Gate Road, San Zao Town, Jin Wan District, Zhuhai, Guangdong. Patentee before: ZHUHAI MIDI TAIKE BIO-PHARMACEUTICAL CO.,LTD. |
|
| TR01 | Transfer of patent right |